Key Points
- Insider David Bredt sold 6,567 shares on December 31 at an average price of $30.05 for $197,338.35, leaving him with 404,075 shares — a 1.60% decrease in his ownership (valued at about $12.14M).
- This sale continues a pattern of recent disposals by Bredt, who also sold 8,500 shares on December 15 (avg $30.02), November 17 (avg $25.19) and October 15 (avg $25.79).
- Rapport shares opened at $27.52 (52-week range $6.43–$42.27) with a $1.31B market cap, and analysts are largely positive with a consensus rating of “Moderate Buy” and a $48.33 average target price.
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 2,840 shares of Rapport Therapeutics stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $30.05, for a total transaction of $85,342.00. Following the completion of the sale, the insider directly owned 296,991 shares in the company, valued at approximately $8,924,579.55. This represents a 0.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Rapport Therapeutics Stock Down 2.1%
Rapport Therapeutics stock opened at $27.52 on Tuesday. The firm has a 50 day moving average price of $28.26 and a 200-day moving average price of $22.31. Rapport Therapeutics, Inc. has a twelve month low of $6.43 and a twelve month high of $42.27. The company has a market capitalization of $1.31 billion, a P/E ratio of -10.15 and a beta of 1.63.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.06. Equities analysts expect that Rapport Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.
Institutional Investors Weigh In On Rapport Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of RAPP. Capital International Investors grew its stake in Rapport Therapeutics by 30.7% during the third quarter. Capital International Investors now owns 3,402,529 shares of the company's stock valued at $101,055,000 after acquiring an additional 800,000 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Rapport Therapeutics by 46.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,626,538 shares of the company's stock valued at $48,308,000 after purchasing an additional 519,047 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in shares of Rapport Therapeutics by 181.2% in the third quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company's stock worth $45,949,000 after purchasing an additional 997,000 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Rapport Therapeutics by 4.1% in the second quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company's stock worth $13,129,000 after purchasing an additional 45,063 shares during the period. Finally, Vestal Point Capital LP purchased a new stake in shares of Rapport Therapeutics in the third quarter worth $28,215,000.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on RAPP. The Goldman Sachs Group restated a "buy" rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Rapport Therapeutics in a research note on Wednesday, October 8th. Citizens Jmp upped their price target on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the company a "market outperform" rating in a research note on Friday, November 7th. Wells Fargo & Company set a $51.00 price objective on shares of Rapport Therapeutics in a report on Friday, December 19th. Finally, Wall Street Zen raised shares of Rapport Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, December 14th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $48.33.
View Our Latest Report on RAPP
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
